Evidence-based guidelines to antithrombotic and thrombolytic therapy

October 2008
Critical Care Nurse;Oct2008, Vol. 28 Issue 5, p10
Academic Journal
The article reports on the publication of the 8th edition of "Antithrombotic and Thrombolytic Therapy: ACCP Guidelines," by the American College of Chest Physicians. The guidelines offer an extensive critical review of the literature related to the thromboembolic disorders. The clinical trials, recommendations and clinical questions are included in each chapter.


Related Articles

  • NEUROFLO IN STUDY FOR STROKE AFTER ATTEMPTED THROMBOLYSIS.  // Biotech Equipment Update;Sep2007, Vol. 15 Issue 9, p5 

    The article reports on the extension of Maple Grove, Minnesota-based CoAxia Inc.'s investigation of NeuroFlo perfusion augmentation technology to patients who do not respond to thrombolysis with the drug tissue plasminogen activator (tPA). The company is already conducting studies to demonstrate...

  • Expanding thrombolysis to older adults, others could triple lives saved.  // Geriatrics;Mar1993, Vol. 48 Issue 3, p22 

    The article reports on the expansion of the U.S. guidelines for thrombolytic therapy. Thrombolytic therapy for acute MI saves 7,200 U.S. lives per year and expanding its use to patients with a favorable risk-benefit ratio could triple the number of lives saved. The current eligibility criteria...

  • ASHP Therapeutic Position Statement on Antithrombotic Therapy in Chronic Atrial Fibrillation. Nutescu, Edith A. // American Journal of Health-System Pharmacy;11/1/2007, Vol. 64 Issue 21, p2281 

    The article focuses on the stand of the American Society of Health System Pharmacists (ASHSP) on the use of antithrombotic therapy in patients with atrial fibrillation (AF). The author asserted that ASHSP agrees with the recommendations of the American College of Chest Physicians indicating that...

  • New guidelines for antithrombotic therapy.  // Patient Care;4/15/2001, Vol. 35 Issue 7, p9 

    Features the 2000 guidelines for antithrombotic therapy and treatment of thrombosis published by the American College of Chest Physicians. Effectiveness of combined antiplatelet drugs and aspirin in preventing strokes and mortality; Treatment for acute ischemic strole using recombinant tissue...

  • Antithrombotic Guidelines Take Individual Risk Into Account.  // Pulmonary Reviews;Mar2012, Vol. 17 Issue 3, p4 

    The article presents the updated guidelines on antithrombotic therapy and the prevention of thrombosis from the American College of Chest Physicians (ACCP). It discusses the importance of assessing patients individually for risks for deep venous thrombosis (DVT), venous thromboembolism (VTE) and...

  • Current clinical use of reteplase for thrombolysis. A pharmacokinetic-pharmacodynamic perspective. Martin, U.; Kaufmann, B.; Neugebauer, G. // Clinical Pharmacokinetics;1999, Vol. 36 Issue 4, p265 

    Clinical evaluation of a new thrombolytic agent should start with a dose that provides adequate efficacy and has an acceptably low bleeding risk; this results in a narrow therapeutic window at the upper end of the dose-response curve. Angiographic patency of the infarct-related artery is still...

  • Are We Using Fibrinolytic Agents Often Enough? Marder, Victor J. // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p136 

    Editorial. Addresses the reluctance of physicians to use fibrinolytic therapy. Explanation for such attitude; Mechanism of action of fibrinolytic agents; Acceptance of heparin therapy.

  • Flushing and Locking of Venous Catheters: Available Evidence and Evidence Deficit. Goossens, Godelieve Alice // Nursing Research & Practice;5/14/2015, Vol. 2015, p1 

    Flushing and locking of intravenous catheters are thought to be essential in the prevention of occlusion. The clinical sign of an occlusion is catheter malfunction and flushing is strongly recommended to ensure a well-functioning catheter. Therefore fluid dynamics, flushing techniques, and...

  • Stroke: Widening the therapeutic window? Crunkhorn, Sarah // Nature Reviews Drug Discovery;Aug2008, Vol. 7 Issue 8, p643 

    The article presents a study on different treatment approaches for ischaemic stroke. The only drug that is specifically approved for the treatment of ischaemic stroke is the thrombolytic agent tissue plasminogen-activating factor (tPA), however, it can only be administered within 3 hours after...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics